With increasing antibiotic resistance reported worldwide, there is a great interest in the development of new antibacterial agents for the treatment of severe skin and skin structure infections (SSSIs). SSSIs mainly involve Grampositive pathogens. Although many of older antibiotics remain effective, new drug development remains crucial owing to the increase in drug resistance among the major Gram-positive pathogens. Since 1999 new antibacterial agents have entered the market or are being evaluated in clinical trials for the treatment of SSSIs. These agents have novel mechanism of action and sufficient improvements in potency to overcome resistance. Linezolid, quinupristin-dalfopristin, daptomycin and tigecycline have been approved by the FDA for the treatment of SSSIs. Other antimicrobials (dalbavancin, oritavancin, telavancin) are currently in clinical development for this indication. This review focuses on the chemistry, microbiology, pharmacology, clinical efficacy and safety of several novel antibacterial agents for the treatment of SSSIs.

New and investigational antimicrobials for the treatment of severe skin infections

DE SARRO, Angelina;FERA, Maria Teresa
2008-01-01

Abstract

With increasing antibiotic resistance reported worldwide, there is a great interest in the development of new antibacterial agents for the treatment of severe skin and skin structure infections (SSSIs). SSSIs mainly involve Grampositive pathogens. Although many of older antibiotics remain effective, new drug development remains crucial owing to the increase in drug resistance among the major Gram-positive pathogens. Since 1999 new antibacterial agents have entered the market or are being evaluated in clinical trials for the treatment of SSSIs. These agents have novel mechanism of action and sufficient improvements in potency to overcome resistance. Linezolid, quinupristin-dalfopristin, daptomycin and tigecycline have been approved by the FDA for the treatment of SSSIs. Other antimicrobials (dalbavancin, oritavancin, telavancin) are currently in clinical development for this indication. This review focuses on the chemistry, microbiology, pharmacology, clinical efficacy and safety of several novel antibacterial agents for the treatment of SSSIs.
2008
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/1857314
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact